Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Sol Gel Technologies Ltd (OQ:SLGL)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
Company Contact
Address: Golda Meir 7
NESS-ZIONA 7403650
Tel: N/A
Website: www.sol-gel.com
IR: See website
Key People
Moshe Arkin
Executive Chairman of the Board
Alon Seri-Levy
Chief Executive Officer, Co-Founder, Director
Gilad Mamlok
Chief Financial Officer
Itzik Yosef
Vice President - Operations
Nissim Bilman
Vice President - Quality
Ofra Levy-Hacham
Vice President - Clinical and Regulatory Affairs
Karine Neimann
Vice President - Projects and Planning, Chief Chemist
Dubi Zamir
Vice President - Special Projects
Ofer Toledano
Vice President - Research and Development
Business Overview
Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company's offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
Financial Overview
For the three months ended 31 March 2024, Sol Gel Technologies Ltd revenues increased 55% to $466K. Net loss decreased 41% to $6.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects RESEARCH AND DEVELOPMENT EXPENSES decrease of 43% to $5.3M (expense), GENERAL AND ADMINISTRATIVE EXPENSES decrease of 7% to $1.8M (expense).